Cue Biopharma, Inc. (CUE)
Nasdaq: CUE · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2015
Who owns Cue Biopharma, Inc.
As filed with the SECHolders of 5% or more
3
Bleichroeder LP holds 9.99% of Common Stock, par value $0.001 per share, as its SCHEDULE 13G/A filed Mar 21, 2025 says.
Directors and officers
17
report now, of 36 people on the record since 2017. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Bleichroeder LP
SCHEDULE 13G/A · filed Mar 21, 2025 · Common Stock, par value $0.001 per share · 9.99% in Oct 7, 2024
Driehaus Capital Management LLC
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock
Shao-Lee Lin
SCHEDULE 13D · filed Aug 21, 2026 · Common Stock, $0.001 par value per share ("Common Stock")
Mark E. Strome
SCHEDULE 13G/A · filed Oct 8, 2026 · Common Stock, $0.001 par value per share · reported falling below 5%, from 4.99% in May 16, 2025
Slate Path Capital LP
SCHEDULE 13G/A · filed Feb 14, 2025 · Common stock, par value $0.001 per share · reported falling below 5%
What CUE reports owning in othersstakes of 5% or more, and other ties
1 subsidiary in 1 country, from the list filed with the 10-K filed Mar 16, 2026.
Insider tradesForm 4
15sales
5purchases
0sales on a scheduled plan
3people selling
$2.4Msold, in dollars
$100,000bought, in dollars
Open-market trades on Form 4 from Oct 14, 2025 to Oct 14, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 14, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 36 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Lin Shao-Lee | Chief Executive Officer | 7 | $1.9M | 0 | 0 | $0 |
| Ray Sumita | Chief Legal Compliance Officer | 4 | $300,000 | 0 | 0 | $0 |
| Meluzio Michael Vincent | VP, Prin. Accounting Officer | 4 | $200,000 | 0 | 0 | $0 |
| Sarraf Pasha | director | 0 | $0 | 0 | 5 | $100,000 |